Ignite Creation Date:
2024-05-06 @ 1:19 PM
Last Modification Date:
2024-10-26 @ 1:12 PM
Study NCT ID:
NCT03988036
Status:
COMPLETED
Last Update Posted:
2023-05-15
First Post:
2019-03-07
Brief Title:
A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype Keyriched-1
Sponsor:
West German Study Group
Organization:
West German Study Group
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Breast Cancer |